Duloxetine: A new serotonin/noradrenaline reuptake inhibitor for the treatment of depression

Drugs of Today

Volumn 40, Issue 9, 2004, Pages 773-790

  Rabasseda, Xavier ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; FAMOTIDINE; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MYLANTA; NEW DRUG; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; APPETITE DISORDER; BINDING AFFINITY; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; FATIGUE; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; META ANALYSIS; NAUSEA; NONHUMAN; NORADRENALIN UPTAKE; ORGASM DISORDER; PAIN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; REVIEW; SEROTONIN UPTAKE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STRESS INCONTINENCE; SWEATING; SYSTEMATIC REVIEW; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; CLINICAL TRIALS; DEPRESSIVE DISORDER; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 8344224431     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.9.850497     Document Type: Review

References (120)

1. Goldman, L.S., Nielsen, N.H., Champion, H.C. Awareness, diagnosis, and treatment of depression. J. Gen Intern Med 1999, 14: 569-80.
2. Ashton, A.K., D'Mello, D.A., Dantz, B. et al. Treatment regimens for managing depression in family practice. J Fam Pract 2003, Suppl. S48-60.
3. Attiullah, N., Zimmerman, M. Update on the diagnosis and treatment of depression. Med Health RI 2003, 86: 310-4.
4. Hardy, J., Argyropoulos, S., Nutt, D.J. Venlafaxine: A new class of antidepressant. Hosp Med 2002, 63: 549-52.
5. Beique, J.C., Lavoie, N., de Montigny, C., Debonnel, G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998, 349: 129-32.
6. Wong, D.T., Robertson, D.W., Bymaster, F.P., Krushinski, J.H., Reid, L.R. LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. Life Sci 1988, 43: 2049-57.
7. Wong, D.T., Bymaster, F.P., Mayle, D.A. et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993, 8: 23-33.
8. Bymaster, F.P., Dreshfield-Ahmad, L.J., Threlkeld, P.G. et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001, 25: 871-80.
9. Kasamo, K., Blier, P., de Montigny, C. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: In vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther 1996, 277: 278-86.
10. Koch, S., Hemrick-Luecke, S.K., Thompson, L.K. et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003, 45: 935-44.
11. Kasahara, T., Ishigooka, J., Nagata, E., Murasaki, M., Miura, S. Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine a potential antidepressant. Nihon Shinkei Seishin Yakurigaku Zasshi 1996, 16: 25-31.
12. Jansen, P.J., Oren, P.L., Kemp, C.A., Maple, S.R., Baertschi, S.W. Characterization of impurities formed by interaction of duloxetine HCl with enteric polymers hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose phthalate. J Pharm Sci 1998, 87: 81-5.
13. Smith, J.E., Lakoski, J.M. Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus. Eur J Pharmacol 1997, 323: 69-73.
14. Smith, J.E., Lakoski, J.M. Electrophysiological study of the effects of the reuptake inhibitor duloxetine on serotonergic responses in the aging hippocampus. Pharmacology 1997, 55: 66-77.
15. Fuller, R.W., Hemrick-Luecke, S.K., Snoddy, H.D. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J Pharmacol Exp Ther 1994, 269: 132-6.
16. Thor, K.B. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: Implications for treating stress urinary incontinence. Urology 2003, 62 4, Suppl. 1): 3-9.
17. Chalon, S.A., Granier, L.A., Vandenhende, F.R. et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, controlled study. Neuropsychopharmacology 2003, 28: 1685-93.
18. Thor, K.B., Donatucci, C. Central nervous system control of the lower urinary tract: New pharmacological approaches to stress urinary incontinence in women. J Urol 2004, 172: 27-33.
19. Grothe, D.R., Scheckner, B., Albano, D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004, 24: 621-9.
20. Michel, M.C., Peters, S.L. Role of serotonin and noradrenaline in stress urinary incontinence. BJU Int 2004, 94 (Supl. 1): 23-30.
21. Canavero, S., Bonicalzi, V. Norepinephrine and pain. Pain 2004, 107: 279.
22. Fava, M. The role of the serotonergic and noradrenergic neurotrasmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 2003, 64 (Suppl. 13): 26-9.
23. Marchand, F., Alloui, A., Chapuy, E. et al. The antihyperalgesic effect of venlafaxine in diabetic rats does not involve the opioid system. Neurosci Lett 2003, 342: 105-8.
24. Nitu, A.N., Wallihan, R., Skljarevski, V., Ramadan, N.M. Emerging trends in the pharmacotherapy of chronic pain. Expert Opin Investig Drugs 2003, 12: 545-59.
25. Briley, M. New Hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 2003, 4: 42-5.
26. Norton, P., Zinner, N.R., Yalcin, I., Burnp, R.C. Duloxetine versus placebo in the treatment of stress urinary incontinence. Neurourol Urodyn 2001, 20: Abst. 99.
27. Rueter, L.E., de Montigny, C., Blier, P. Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J Pharmacol Exp Ther 1998, 285: 404-12.
28. Rueter, L.E., Kasamo, K., de Montigny, C., Blier, P. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1998, 357: 600-10.
29. Engleman, E.A., Perry, K.W., Mayle, D.A., Wong, D.T. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 1995, 12: 287-95.
30. Engleman, E.A., Robertson, D.W., Thompson, D.C., Perry, K.W., Wong, D.T. Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J Neurochem 1996, 66: 599-603.
31. Kihara, T., Ikeda, M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 1995, 272: 177-83.
32. Iyengar, S., Bymaster, F.P., Wong, E.T., Ahmad, L., Simmons, R.M.A. Efficacy of the selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain. Eur Neuropsychopharmacol 2002, 12 (Suppl. 3): Abst. P.1.110.
33. Iyengar, S., Bymaster, F.P., Wong, D.T., Ahmad, L., Simmons, R.M.A. Efficacy of the selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain. 21st Annu Sci Meet Am Pain Soc (Mar 14-17, Baltimore) 2002, Abst. 726.
34. Wong, D.T. Duloxetine (LY 248686): An inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Invest Drugs 1998, 7: 1691-9.
35. Tatsumi, M., Groshan, K., Blakely, R.D., Richelson, E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997, 340: 249-58.
36. Katoh, A., Eigyo, M., Ishibashi, C. et al. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. J Pharmacol Exp Ther 1995, 272: 1067-75.
37. Thor, K.B., Katofiasc, M.A. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloraloseanesthetized female cat. J Pharmacol Exp Ther 1995, 274: 1014-24.
38. Brocco, M., Dekeyne, A., Veiga, S., Girardon, S., Millan, M.J. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 2002, 71: 667-80.
39. Jackson, H.C., Needham, A.M., Hutchins, L.J., Mazurkiewicz, S.E., Heal, D.J. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997, 121: 1758-62.
40. Sharma, A., Goldberg, M.J., Cerimele, B.J. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000, 40: 161-7.
41. Skinner, M.H., Kuan, H.Y., Pan, A. et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003, 73: 170-7.
42. Skinner, M.H., Skerjanec, A., Seger, M., Hewitt, R. The effect of food and bedtime administration on duloxetine pharmacokinetics. Clin Pharmacol Ther 2000, 67: Abst. PII-59.
43. Granier, L.A., Vandemhende, F., de Suray, J.M., Grossman, F. Safety and pharmacokinetics of duloxetine, a potential new antidepressant with serotonin and norepinephrine uptake. Eur Neuropsychopharmacol 1999, 9 (Suppl. 5): Abst. P.1.043.
44. DeLong, A.F., Johnson, J.T., Oldham, S.W., Patel, B.R., Hysop, D.L. Disposition of 14C duloxetine after oral administration in man. Faseb J 1995, 9 (4, Part 2): Abst. 4005.
45. Johnson, J.T., DeLong, A.F., Oldham, S.W., Patel, B.R., Hyslop, D.L. Disposition of 14C duloxetine after oral administration in man. Pharm Res 1995, 12 (9, Suppl.): Abst. PPDM 8241.
46. Sachirakul, K., Teng, L.L., Yeo, K.P., Chan, C. Impact of gastric pH and the presence of activated charcoal on the absorption of duloxetine. Clin Pharmacol Ther 2002, 71: Abst. MPI-53.
47. Hua, T.C., Pan, A., Chan, C. et al. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2004, 57: 652-6.
48. Skinner, M.H., Ni, L., Kuan, H.Y., Knadler, M.P., Gonzales, C. Effect of duloxetine on CYP2D6. Clin Pharmacol Ther 2001, 69: Abst. PIII-59.
49. di Virgilio, S.N., Gonzales, C., Knadler, M.P. et al. Effect of duloxetine (DU) on CYP1A2-mediated drug metabolism and the pharmacokinetics (PK) of theophylline (THEO). Clin Pharmacol Ther 2002, 71: Abst. TPI-78.
50. Gobert, A., Rivet, J.M., Cistarelli, J.M., Millan, M.J. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem 1997, 68: 1326-9.
51. Gobert, A., Rivet, J.M., Cistarelli, L., Melon, C., Millan, M.J. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 1997, 69: 2616-9.
52. Millan, M.J., Brocco, M., Veiga, S. et al. WAY 100,635 enhances both the 'antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. Eur J Pharmacol 1998, 341: 165-7.
53. Skinner, M.H., Weerakkody, G. Duloxetine does not exacerbate the effects of alcohol on psychometric tests. Clin Pharmacol Ther 2002, 71: Abst. TPII-45.
54. Turcotte, J.E., Debonnel, G., de Montigny, C., Hebert, C., Blier, P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001, 24: 511-21.
55. Chalon, S., Granier, L.A., Vandenhende, F. et al. Duloxetine: Clinical evidence of serotoninergic and noradrenergic reuptake blockade. Clin Pharmacol Ther 2001, 69: Abst. PI-67.
56. Chalon, S., Granier, L.A., Vandenhende, F. et al. Duloxetine: Pharmacodynamic evidence in man of dual reuptake inhibition. Eur Neuropsychopharmacol 2001, 11 (Suppl. 3): Abst. 1072.
57. Chalon, S., Granier, L.A., Vandenhende, F., Lainey, E., Potter, W.Z. Duloxetine affects sleep architecture with antidepressant like pattern. Clin Pharmacol Ther 2001, 69: Abst. PII-65.
58. Ishigooka, J., Nagata, E., Takahashi, A. et al. Simultaneous monitoring of inhibition of serotonin uptake by platelets and plasma drug concentrations following administration of duloxetine, a new antidepressant candidate, to healthy volunteers. Curr Ther Res 1997, 58: 679-92.
59. Ishigooka, J., Murasaki, M. First open study with new antidepressant LY248686 (duloxetine) for depression in Japan. Eur Neuropsychopharmacol 1996, 6 (Suppl. 3): Abst. P-4-19.
60. Berk, M., du Plessis, A.D., Birkett, M., Richardt, D. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. Int Clin Psychopharmacol 1997, 12: 137-40.
61. Detke, M.J., Lu, Y., Goldstein, D.J., McNamara, R.K., Demitrack, M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002, 36: 383.
62. Detke, M., Lu, Y., Goldstein, D.J., Mallinckrodt, C. The efficacy of duloxetine 60 mg qd for the treatment of major depression. J Clin Pharmacol 2002, 42: Abst. 91.
63. Detke, M.J., Lu, Y., Goldstein, D.J., Hayes, J.R., Demitrack, M.A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002, 63: 308-15.
64. Detke, M., Lu, Y., Goldstein, D.J., Demitrack, M.A. Duloxetine 60 mg QD is efficacious in the treatment of depression. Eur Neuropsychopharmacol 2002, 12 (Suppl. 3): Abst. P.1.109.
65. Detke, M.J., Lu, Y., Goldstein, D.J., Demitrack, M.A. Duloxetine 60 mg QD is an efficacious depression treatment. Annu Meet Am Psychiatr Assoc (May 18-23, Philadelphia) 2002, Abst. NR123.
66. Goldstein, D.J., Mallinckrodt, C., Lu, Y., Demitrack, M.A. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002, 63: 225-31.
67. Goldstein, D.J., Mallinckrodt, C., Lu, Y., Demitrack, M.A. Efficacy and safety of duloxetine in the treatment of major depresson. Eur Neuropsychopharmacol 2001, 11 (Suppl. 3): Abst. 1076.
68. Goldstein, D.J. Efficacy of duloxetine in the treatment of major depression. 7th World Congr Biol Psychiatry (Jul 1-6, Berlin) 2001, Abst. P025-07.
69. Mallinckrodt, C., Goldstein, D.J., Lu, Y. et al. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. Eur Neuropsychopharmacol 2002, 12 (Suppl. 3): Abst. P.1.107.
70. Goldstein, D.J., Lu, Y., Detke, M.J. et al. Duloxetine versus paroxetine in the treatment of depression. Annu Meet Am Psychiatry Assoc (May 18-23, Philadelphia) 2002, Abst. NR420.
71. Goldstein, D.J., Lu, Y., Detke, M. et al. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Psychopharmacol 2002,16 (3, Suppl.): Abst. D30.
72. Detke, M., Gilaberte, I., Perahia, D.G. et al. Duloxetine vs. placebo in the prevention of relapse of major depressive disorder. Eur Coll Neuropsychopharmacol, September 20-24, Prague 2003.
73. Wohlreich, M.M., Kennedy, J.S., Mallinckrodt, C., Raskin, J., Tran, P.V. Open-label duloxetine treatment of major depression in patients age 65 or older. J Am Geriatr Soc 2003, 51 (4, Suppl.): Abst P257.
74. Wohlreich, M.M., Mallinckrodt, C.H., Watkin, J.G., Prakash, A. Duloxetine treatment of MDD: Safety and efficacy. 157th Annu Meet Am Psychiatr Assoc (May 1-May 6, New York) 2004, Abst NR712.
75. Detke, M., Gilaberte, I., Perahia, D. et al. Duloxetine vs placebo in the prevention of relapse of major depressive disorder. Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): S261.
76. Wang, F., Wohlreich, M.M., Detke, M.J. Effect of duloxetine on sexual functioning during treatment of MDD. 157th Annu Meet Am Psychiatr Assoc (May 1-May 6, New York) 2004, Abst NR818.
77. Brannan, S.K., Mallinckrodt, C.H., Detke, M.J., Watkin, J.G., Tollefson, G.D. Assessing onset of action in clinical trials of duloxetine 60 mg QD. 43rd Annu NCDEU Meet (May 27-May 30, Boca Raton) 2003, Abst II - 32.
78. Wohlreich, M.M., Brannan, S.K. et al. Onset of improvement in emotional and painful physical symptoms of depression with duloxetine treatment. 4th Int Forum Mood Anxiety Disord (Nov 19-Nov 21, Monte-Carlo) 2003, Abst P38.
79. Wohlreich, M., Mallinckrodt, C., Lu, Y., Detke, M. Treatment efficacy of duloxetine 60 mg QD for patients with major depression with painful physical symptoms. 22nd Annu Sci Meet Am Pain Soc (Mar 20-Mar 23, Chicago) 2003, Abst 933.
80. Hirschfeld, R.M.A., Mallinkrodt, C., Clemens, J.W., Detke, M.J. Early symptom response during treatment with duloxetine 60 mg: HAMD17 items. 157th Annu Meet Am Psychiatr Assoc (May 1-May 6, New York) 2004, Abst NR536.
81. Raskin, J., Goldstein, D.J., Mallinckrodt, C.H., Ferguson, M.B. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003, 64: 1237.
82. Detke, M., Gilaberte, I., Perahia, D.G. et al. Duloxetine vs placebo in the prevention of relapse of major depressive disorder. 4th Int Forum Mood Anxiety Disord (Nov 19-Nov 21, Monte-Carlo) 2003, Abst P07.
83. Detke, M.J., Gilaberte, I., Perahia, D.G., Wang, F., Lee, T.C., Tran, P.V. Duloxetine versus placebo in the prevention of relapse of MDD. 157th Annu Meet Am Psychiatr Assoc (May 1-May 6, New York) 2004, Report sessions, Abst 20.
84. Goldstein, D.J. et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004, 45: 17.
85. Detke, M.J., Tran, P.V., Goldstein, D.J., Mallinckrodt, C., Demitrack, M.A. Effects of the antidepressant duloxetine on sexual function. Annu Meet Am Psychiatr Assoc (May 18-23, Philadelphia) 2002, Abst. NR121.
86. Falissard, B., Lothgren, M., Perahia, D., Garcia-Cebrian, A. Meta-analyses of duloxetine in the treatment of MDD. 4th Int Forum Mood Anxiety Disord (Nov 19-Nov 21, Monte-Carlo) 2003, Abst P13.
87. Hay, D., Wohlreich, M., Mallinckrodt, C., Watkin, J. Open-label duloxetine treatment of major depression: Comparisons between elderly (age >65) and younger (age <65) patients. 11th Int Congr Int Psychogeriatr Assoc (Aug 17-Aug 22, Chicago) 2003, Abst PA-043.
88. Delgado, P.L., Mallinckrodt, C.H., Wang, F. et al. Comparison of sexual functioning in patients receiving duloxetine or paroxetine: Acute- and long-term. 4th Int Forum Mood Anxiety Disord (Nov 19-Nov 21, Monte-Carlo) 2003, Abst P06.
89. Thase, M.E., Lu, Y., Joliat, M.J., Treuer, T., Detke, M.J. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. 4th Int Forum Mood Anxiety Disord (Nov 19-Nov 21, Monte-Carlo) 2003, Abst P32.
90. Thase, M.E. et al. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. 156th Annu Meet Am Psychiatr Assoc (May 17-May 22, San Francisco) 2003, Abst NR840.
91. Mallinckrodt, C. et al. Minimal effect of the antidepressant duloxetine on body weight. 155th Annu Meet Am Psychiatr Assoc (May 18-May 23, Philadelphia) 2002, Abst NR441.
92. Tran, P.V., Detke, M.J., Goldstein, D.J., Mallinckrodt, C., Demitrack, M.A. Safety and tolerability of the antidepressant duloxetine. Annu Meet Am Psychiatr Assoc (May 18-23, Philadelphia) 2002, Abst. NR425.
93. Tran, P., Mallinckrodt, C., Detke, M., Goldstein, D.J., Demitrack, M.A. Safety and tolerability of the antidepressant duloxetine. Eur Neuropsychopharmacol 2002, 12 (Suppl. 3): Abst. P.1.111.
94. Tran, P., Detke, M.J., Goldstein, D.J., Mallinckrodt, C., Demitrack, M.A. Safety and tolerability of the antidepressant duloxetine. J Clin Pharmacol 2002, 42: Abst. 90.
95. Swindle, R.W., Mallinckrodt, C.H., Rosenbaum, J., Lu, Y., Watkin, J.G., Detke, M.J. Efficacy of duloxetine treatment: Analysis of pooled data from six placebo- and SSRI-controlled clinical trials. 157th Annu Meet Am Psychiatr Assoc (May 1-May 6, New York) 2004, Abst NR722.
96. Mallinckrodt, C.H., Watkin, J.G., Liu, C., Wohlreich, M.M., Raskin, J. Duloxetine in the treatment of MDD: A comparison of efficacy in patients with and without melancholic features. 157th Annu Meet Am Psychiatr Assoc (May 1-May 6, New York) 2004, Abst NR719.
97. Goldstein, D.J., Detke, M., Lu, Y., Demitrack, M.A. The antidepressant duloxetine reduces anxiety symptom severity. Eur Neuropsychopharmacol 2002, 12 (Suppl. 3): Abst. P.1.105.
98. Goldstein, D.J., Detke, M.J., Lu, Y., Demitrack, M.A. Duloxetine reduces anxiety symptom severity. Annu Meet Am Psychiatr Assoc (May 18-23, Philadelphia) 2002, Abst. NR421.
99. Dunner, D.L., Goldstein, D.J., Mallinckrodt, C., Lu, Y., Detke, M.J. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003, 18: 53-61.
100. Patrick, D.L., Martin, M.L., Bushnell, D.M. et al. Quality of life of women with urinary incontinence: Further development of the incontinence quality of life instrument (I-QOL). Urology 1999, 53: 71-6.
101. Mulcahy, J.J., Laddu, A.R., Faries, D.E. et al. Efficacy and safety of duloxetine in stress incontinence patients. Neurourol Urodyn 1996, 15: 395-6.
102. Zinner, N.R. Duloxetine: A serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence. Expert Opin Investig Drugs 2003, 12: 1559-66.
103. Norton, P.A., Zinner, N.R., Yalcin, I., Bump, R.C. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002, 187: 40-8.
104. Dmochowski, R.R., Miklos, J.R., Norton, P.A. et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003, 170 (4 Pt 1): 1259-63.
105. Van Kerrebroeck, P., Abrams, P., Lange, R. et al. Duloxetine vs. placebo in the treatment of stress urinary incontinence: Phase 3 results from Europe and Canada. Eur Urol Suppl 2003, 2: Abst 107.
106. Millard, R.J., Moore, K., Rencken, R., Yalcin, I., Bump, R.C. Duloxetine vs placebo in the treatment of stress urinary incontinence: A four-continent randomized clinical trial. BJU Int 2004, 93: 311
107. Schagen van Leeuwen, J.H., Elser, D., Freeman, R. et al. Controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment, and no treatment in women with stress urinary incontinence (SUI). Eur Urol Suppl 2004, 3: Abst 197.
108. Ghoniem, G.M., Elser, D.M., Freeman, R. et al. Controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment, and no treatment in women with stress urinary incontinence (SUI). J Urol 2004, 171 (4, Suppl.): Abst 1239.
109. Bump, R., Hooper, C., Peng, G., Yalcin, I. Comparing dry days in women with different stress urinary incontinence severity levels treated with duloxetine and placebo. Eur Urol Suppl 2004, 3: Abst 196.
110. Goldstein, D.J., Lu, Y., Mallinckrodt, C. et al. Duloxetine: A potential new treatment for depressed patients with comorbid pain. 10th World Congr Pain (Aug 17-22, San Diego) 2002, Abst. 1254-P170.
111. Goldstein, D.J., lyengar, S., Mallinckrodt, C. et al. Duloxetine: A potential new treatment for depressed patients with comorbid pain. 21st Annu Sci Meet Am Pain Soc (Mar 14-17, Baltimore) 2002, Abst. 789.
112. Wernicke, J.F., Lu, Y., D'Souza, D.N. et al. Duloxetine at doses of 60 mg QD and 60 mg BID is effective treatment of diabetic neuropathic pain. Am Acad Neurol, April 24-May 1, San Francisco 2004.
113. Arnold, L., Crofford, L., Lu, Y. et al. A double-blind trial comparing duloxetine to placebo in the treatment of fibromyalgia with or without major depressive disorder. American Psychosomatic Society 2004.
114. Wernicke, J.F., Rosen, A., Lu, Y., Lee, T.C., Knopp, K., Goldstein, D.J. The safety of duloxetine in the long-term treatment of diabetic neuropathic pain. 157th Annu Meet Am Psychiatr Assoc (May 1-May 6, New York) 2004, Abst NR538.
115. Raskin, J., Wang, F., Stroud, C., Clemens, J. Duloxetine for patients with diabetic neuropathic pain: A six-month open label safety study. 23rd Annu Sci Meet Am Pain Soc (May 6-May 9, Vancouver) 2004, Abst 755.
116. Detke, M., Goldstein, D., Lu, Y., Iyengar, S., Lee, T. Efficacy of duloxetine in the treatment of the pain associated with diabetic neuropathy. 18th Int Diabetes Fed Congr (Aug 24-Aug 29, Paris) 2003, Abst 912.
117. Wernicke, J.F., Lu, Y., D'Souza, D., Waninger, A., Tran, P.V. Duloxetine at doses of 60 mg and 60 mg b.i.d. is effective in the treatment of diabetic neuropathic pain. 157th Annu Meet Am Psychiatr Assoc (May 1-May 6, New York) 2004, Abst NR537.
118. Wernicke, J.F., Lu, Y., D'Souza, N., Waninger, A., Tran, P.V. Duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP). Neurology 2004, 62 (7, Suppl. 5): Abst P03.001.
119. Mallinckrodt, C., Tran, P.V., Detke, M.J., Goldstein, D.J., Demitrack, M.A. Minimal effect of the antidepressant duloxetine on body weight. Annu Meet Am Psychiatr Assoc (May 18-23, Philadelphia) 2002, Abst. NR442.
120. Detke, M., Tran, P., Goldstein, D.J., Mallinckrodt, C., Demitrack, M.A. The antidepresant duloxetine lacks adverse cardiovascular effects. Annu Meet Am Psychiatr Assoc (May 18-23, Philadelphia) 2002, Abst. NR122.